Over nearly three decades … Lilly has raised the list price on its most widely used insulin product, Humalog, by more than 1,000 percent, which is why I greet Lilly’s announcement of the $35 a month out of pocket cap for the commercially insured with both joy and sorrow.
Is it, Lilly had a great gig going with those Humalog price run ups and now knows all good things must end? Or, give a little to avoid being forced to give a great deal more on general pharmaceutical pricing? And, what about those who are not commercially insured, who must seek this insulin price relief for out of pocket purchases, for example, by applying to Lilly’s co-pay support program? What will happen to them?